Bryan Garnier - Inditex (ITX SM) (ITX SM) INDITEX: FY21 results: Strong current trading in spite of weak Q4 numbers | BUY | Under Review

Report

Bryan Garnier

Cedric Rossi

INDITEX: FY21 results: Strong current trading in spite of weak Q4 numbers | BUY | Under Review

INDITEX - BUY | Under Review
FY21 results: Strong current trading in spite of weak Q4 numbers

FY21 sales a touch below expectations as the Omicron variant weighed on Q4 performance
Q4 GM and EBIT miss
Reassuring current trading with +33% YoY (1st Feb-13th Mar) but Russia will hamper future growth

16/03/2022 1 EN

Underlying

Inditex (ITX SM)

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Cedric Rossi

Other Reports on these Companies

Sabadell

INDITEX: 4Q’24 RESULTS (ANÁLISIS BANCO SABADELL)

4Q'24 vs. 4Q'23 Results Sales: € 11.21 Bn (+8.4% vs. +8.0% BS(e) and +7.9% consensus); EBIT: € 1.881 Bn (+16.3% vs. +9.9% BS(e) and +12.1% consensus); Net Profit: € 1.417 Bn (+10.8% vs. +10.7% BS(e) and +13.1% consensus); FY2024 vs. FY2023 Results Sales: € 38.632 Bn (+7.5% vs. +7.3% BS(e) and +7.3% consensus); EBIT: € 7.554 Bn (+10.9% vs. +9.4% BS(e) and +9.9% consensus); Net Profit: € 5.866 Bn (+9.0% vs. +9.0% BS(e) and +9.6% consensus);

EUR 100.00

March 12, 2025 March 12, 2025 1 EN

Sabadell

INDITEX: RDOS. 4T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 4T'24 vs 4T'23: Ventas: 11.210 M euros (+8,4% vs +8,0% BS(e) y +7,9% consenso); EBIT: 1.881 M euros (+16,3% vs +9,9% BS(e) y +12,1% consenso); BDI: 1.417 M euros (+10,8% vs +10,7% BS(e) y +13,1% consenso); Rdos. 2024 vs 2023: Ventas: 38.632 M euros (+7,5% vs +7,3% BS(e) y +7,3% consenso); EBIT: 7.554 M euros (+10,9% vs +9,4% BS(e) y +9,9% consenso); BDI: 5.866 M euros (+9,0% vs +9,0% BS(e) y +9,6% consenso).

EUR 100.00

March 12, 2025 March 12, 2025 1 ES

Sabadell

INFORME DIARIO 12 MARZO + RDOS. EUROPA 4T’24. PREVIEWS (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, INDITEX. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’24 que se publicarán en España y Europa en los próximos días. Trump aumenta los aranceles y pasa factura a la complacencia en Europa Nueva jornada de caídas a ambos lados del Atlántico tras el nuevo anuncio de D. Trump que duplicaría los aranceles al acero y al aluminio procedentes de Canadá hasta el 50%, aunque luego dio marcha atrás p...

EUR 100.00

March 12, 2025 March 12, 2025 1 ES

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

21h / 24m 21h / 24m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

21h / 30m 21h / 30m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

21h / 36m 21h / 36m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

INDITEX: FY21 results: Strong current trading in spite of weak Q4 numbers | BUY | Under Review

INDITEX: 4Q’24 RESULTS (ANÁLISIS BANCO SABADELL)

INDITEX: RDOS. 4T’24 (ANÁLISIS BANCO SABADELL)

INFORME DIARIO 12 MARZO + RDOS. EUROPA 4T’24. PREVIEWS (ANÁLISIS BANCO SABADELL)

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe